logo

Biotechnology & Drugs News

Share

Novartis To Invest $250 Mln Over 5 Yrs To Advance R&D Of New Treatments Against NTDs And Malaria

BridgeBio Pharma Announces Early Positive Data For BBP-812 For Canavan Disease

Merck: FDA Approves VAXNEUVANCE For Prevention Of Invasive Pneumococcal Disease In Infants, Children

Moderna Announces New Clinical Data On Bivalent (Omicron) COVID Booster Candidate, MRNA-1273.214

Biocartis Reports Deal With AstraZeneca For Development Of Companion Diagnostic Test For Tagrisso